Our Blog | Biosimilars & Generics | AAM

New White Paper - Read AAM Report on Drug Shortages

Meitheal Manufacturer

Oct 14, 2022 | Jewel Smith

Member Spotlight: Meitheal Pharmaceuticals

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Oct 3, 2022 | Monét Stanford

Generics & Biosimilars Continue to Reward Patients, Employers and Taxpayers

October, 26, New Carrollton, MD

Sep 29, 2022 | Erica Klinger

October Can Now Afford to do More to Support Her Mental Health

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Sep 15, 2022 | Model B

IQVIA White Paper: Pharmacy Discount Card Utilization and Impact

Sep 6, 2022 | Craig Burton

Explosive Growth in Drug Discount Cards is a Symptom of a Broken System

AAM All Access Podcast

Jul 28, 2022 | Dan Leonard

AAM All Access Podcast: Medicare Drug Price Negotiation is Bad for Patients

AAM Statement on H3

Jul 25, 2022 | Craig Burton

Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending

AAM All Access Podcast

Jul 21, 2022 | Dan Leonard

AAM All Access Podcast: CMMB’s Urgent Mission

Doesn't Add Up patient photo

Jul 20, 2022 | Craig Burton

The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations

Senior patient picking up medicines at a pharmacy

Jul 20, 2022 | Craig Burton

Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly

A pharmacological manufacturing and bottling factory in a bright laboratory environment

Jul 20, 2022 | Craig Burton

Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers

Percent of Patients Who Paid the Full Cost of a Generic at Least Once, 2017 and 2020

Jul 12, 2022 | Monét Stanford

Despite Enrollment In Medicare Prescription Drug Coverage, Over Half of All Seniors Pay Full Cost for Many Generic Drugs